Individualized dosing of tyrosine kinase inhibitors: are we there yet?

Area of Science:

• Pharmacology
• Oncology

Background:

• Tyrosine kinase inhibitors (TKIs) are standard cancer treatments administered at fixed oral doses.
• Significant pharmacokinetic (PK) variability exists among patients receiving TKIs.
• This fixed-dose approach can lead to suboptimal drug exposure, potentially impacting treatment efficacy and safety.

Purpose of the Study:

• To evaluate if TKIs used for solid tumors meet the criteria for dose individualization.
• To explore the potential benefits of personalized dosing strategies in TKI therapy.

Main Methods:

• A comprehensive review of existing literature on TKIs and their pharmacokinetics.
• Analysis of retrospective data to identify potential target trough concentration (Ctrough) levels.

Main Results:

• Current data suggest specific Ctrough targets for imatinib (1100 ng/ml), continuously dosed sunitinib (37.5 ng/ml), intermittently dosed sunitinib (50 ng/ml), and pazopanib (20 μg/ml).
• Despite limitations, these levels indicate potential for dose individualization.

Conclusions:

• Dose individualization of TKIs holds promise for optimizing cancer treatment outcomes.
• Prospective clinical trials are necessary to confirm the impact of dose individualization on treatment efficacy and patient safety.